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aspects of diagnostic testing was coordinated to evaluate
testing devices with the goal of significantly expanding the
ability to mass screen Americans to preserve lives and
facilitate the safe return to work and school. Focal points
included: laboratory and clinical device evaluation of the
limit of viral detection, sensitivity, and specificity of devices
in controlled and community settings; regulatory expertise
to provide focused attention to barriers to device approval
and distribution; usability testing from the perspective of
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device limitations, and engineering assessment to evaluate
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I. INTRODUCTION
The COVID-19 pandemic has presented unprecedented chal-
lenges including the critical need to efficiently develop accurate
diagnostic tests to rapidly detect symptomatic and asymptomatic
infections [1]–[3]. The urgency to develop novel diagnostic
devices and scale up existing testing technologies led Congress
to appropriate $1.5 billion to the National Institutes of Health
(NIH) which, in turn, established the Rapid Acceleration of
Diagnostics (RADxSM) initiative with the overall goal to signif-
icantly expand the ability to mass screen Americans to preserve
lives and facilitate the safe return to work and school [1]. RADx
Tech was born out of this program with the specific charge to
identify, accelerate the development of, scale up, and deploy
innovative point-of-care technologies. To meet the critical need
for test verification and clinical studies of novel SARS-CoV-2
diagnostics within RADx Tech, a pre-existing set of Point-of-
Care Technology Research Network (POCTRN) development
centers across the United States were pivoted to provide this
critical infrastructure, knowledge, and expertise.
Already well established prior to the pandemic, POCTRN
uses a partnership model to improve clinical care through
exploratory development of point-of-care test (POCT) devices,
clinical needs assessment, training of technology developers,
clinical testing, and the provision of administrative support
[4]–[6]. The device verification needs for RADx Tech were
quickly met by leveraging the academic and medical partners
within one of the National Institute of Biomedical Imaging and
Bioengineering (NIBIB)’s funded POCTRN centers, the Atlanta
Center for Microsystems Engineered Point-of-Care Technolo-
gies (ACME POCT) [7]. Established in 2018, ACME POCT
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Figure 1. (a). Original organization of ACME POCT. Launched in Sept 2018, the ACME POCT funded by grant U54EB027690 was established
to enable inventors with their microsystems-based POC technologies for cardiac, pulmonary hematologic and sleep applications by assisting in
defining specific clinic need, conducting clinic validation, and refining these technologies, with the objective of accelerating the path to translation
and clinic adoption. (b). High level organizational chart for the newly formed TVC multi-disciplinary and multi-institutional team. Tiers 1 and 2 as
shown were largely established part of ACME POCT and quickly pivoted to address the goals of the RADx TVC. Additionally, Tier 3 was assembled
to address new areas of need. Evaluation and education function from the tech Training & Dissemination core were moved to the Tier 1 oversight
function and the regulatory function was strengthened considerably within the Tier 2 Team. Emory, Emory University and Emory Healthcare; GT,
Georgia Institute of Technology; Children’s, Children’s Healthcare of Atlanta; Grady, Grady Hospital.
is a partnership between Emory University (Emory), Georgia
Institute of Technology (GT), and Children’s Healthcare of
Atlanta (Children’s). Another POCTRN center, the Center for
Advancing Point of Care Devices in Heart, Lung, Blood, and
Sleep Disorders (CAPCaT), funded by the National Heart, Lung,
and Blood Institute (NHLBI), was enlisted as a secondary and
complementary test verification site and was engaged on an
as-needed basis. CAPCaT, also established in 2018, is a partner-
ship between the University of Massachusetts Medical School
(UMMS) and the University of Massachusetts Lowell (UML).
Fig. 1 illustrates how the original NIBIB-funded ACME
POCT organization (Fig. 1(a)) was leveraged to stand up the new
“Test Verification Core” (TVC) supplement for this emergency
purpose (Fig. 1(b)). The TVC was tasked with serving as the
national test verification hub for RADx Tech by providing inde-
pendent and impartial assessment of the design and performance
of promising COVID-19 diagnostic tests developed by private
companies and academic inventors [8].
To provide this important “testing of the tests,” the TVC had
to quickly assemble a multi-institutional, transdisciplinary team
that included the following major focal points for expertise and
activities: laboratory and clinical device evaluation to under-
stand the limit of viral detection, sensitivity, and specificity
of candidate devices in controlled and community settings;
strengthened regulatory expertise to provide more focused at-
tention to identify and overcome barriers to device approval and
distribution; usability testing from the perspective of patients and
those using the tests to identify and overcome device limitations,
and engineering assessment to evaluate robustness of design
including human factors, manufacturability, and scalability.
The already established ACME POCT (Fig. 1(a)) was well
positioned to assume the TVC responsibility, as the pre-COVID
goal of the ACME POCT was to assist microsystems-based
POC technology inventors from across the country by providing
clinical needs assessments, clinical testing and validation, and
technology refinement, with the objective of accelerating the
path through translation, regulatory compliance, manufacturing,
and clinical adoption [7], [9]. Receipt of a supplement from
NIBIB in May 2020 launched this new TVC directive by quickly
redirecting the existing ACME POCT goals, processes, and
personnel to pivot the focus to verification of the performance
of COVID-19 diagnostic tests including sensitivity, specificity,
limit of detection (LOD), and cross-reactivity with other viruses.
The TVC was able to capitalize on the existing ACME POCT
expertise and infrastructure and made select strategic additions
from the partner sites including Emory, GT, and Children’s.
Sites and personnel were quickly organized and mobilized to
establish several focused sub cores comprised of biosafety level
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(BSL) 2 and 3 laboratories, clinical bio-banks of COVID-19
positive or negative patient specimens (including nasopharyn-
geal, nasal, and saliva samples), community-based collection
sites for prospective testing to compare novel diagnostic tech-
nologies with the reference method RT-PCR test, and engineer-
ing design and human factors assessment labs.
This quickly assembled but carefully structured TVC was
organized to provide assessments and consultation on a wide
array of diagnostic technologies (>50 devices to date) to provide
unbiased evaluations of candidate COVID-19 testing devices.
The sub cores within the TVC were empowered to conduct
independent evaluations of the devices that were delivered
to the TVC. These reviews were then collated by the team
evaluators and collectively reviewed by the TVC team using
NIH study section type reviews. An impact score was generated
and a formal evaluation report was submitted to the NIBIB. The
TVC evaluations were factored into the NIH go/no-go decisions
regarding further support for testing and manufacturing of
those technologies towards making them rapidly available to
the public. This article provides a description of the formation
and operations of the TVC, elucidates center processes and
efforts, and illustrates how a center can provide a model of
vision, leadership, coordination, and services to develop and
evaluate novel COVID-19 testing devices and thus contribute
to the national effort to improve large scale diagnostic testing
efforts.
Device verification requires a wide variety of expertise and
technical skillsets, and to be done well, must be conducted in
a coordinated and integrated manner that is highly dependent
upon strong communication and collaboration [4], [7]. Below
are descriptions of the key functions of the TVC including
1) Leadership & Administrative including evaluation and ed-
ucation functions; 2) Engineering Design and Human Factors;
3) Clinical/Translational Validation including virology, clinical
population testing and sample collection and clinical laboratory
assessment; 4) Regulatory. While these sub cores were staffed to
function as independent units, strong leadership oversight and a
carefully designed communication strategy were implemented
to coordinate and integrate their activities to generate a well-
informed, unified, multi-disciplinary, expert recommendation
for each device that entered the TVC.
Through a $20M supplement, a similar but smaller scale
TVC was organized at CAPCaT. They also were able to pivot
their pre-COVID 19 activities to assist RADx Tech with the
verification of the performance of COVID-19 diagnostic tests
including sensitivity, specificity, limit of detection (LOD), and
cross-reactivity with other viruses. Because CAPCaT lacks a
BSL-3 facility for direct virology testing, however, the ACME
POCT served as the primary TVC site calling on CAPCaT for
additional testing efforts. The verification operations at CAPCaT
were housed at the Massachusetts Medical Device Development
Center (M2D2). M2D2 is an incubator program for early-stage
medical device and biotech startups, a joint program between
University of Massachusetts Lowell and University of Mas-
sachusetts Medical School. M2D2 operates three lab facilities;
two on the UMass Lowell campus in Lowell, Massachusetts
and one on the UMass Medical School campus in Worcester,
Massachusetts.
II. LEADERSHIP & ADMINISTRATIVE INCLUDING EVALUATION
AND EDUCATION FUNCTIONS
The “team science” literature routinely indicates that progress
in scientific research benefits from diverse sources of ideas, in-
novation, and interdisciplinarity [10]–[12]. Quickly developing
a TVC team structure and communication strategy that could
develop efficient and effective pathways to facilitate compre-
hensive evaluation of a largely heterogeneous set of COVID-
19 testing devices required experts from different disciplinary
backgrounds to work collaboratively and across research area
boundaries to synthesize their unique expertise, institutional
resources and strengths, and methodologies.
To address the need for a quick launch of this team science
approach, the existing ACME POCT leaders and key personnel
worked together to address the new TVC priorities by pivoting
leadership focus and activities, adjusting goals related to this new
urgency and establishing an associated organizational structure
and aligned communication strategy. The ACME POCT leader-
ship already in place (Fig. 1(a)) included experts in engineering,
clinical and clinical need assessment, regulatory, evaluation
and biostatistical, educational, and administrative domains. Key
personnel from the existing ACME POCT team as shown in
Fig. 1(a) assessed the current area strengths and compared
them to the TVC specific needs to focus efforts on identifying
and recruiting the additional skillsets and expertise needed to
address the unique TVC aims. In response, the ACME POCT
leaders identified and recruited resources and targeted expertise
throughout the partner institutions in virology, microbiology,
laboratory diagnostics, biological specimen collection, clinical
research, and biorepositories to join the team. The team grew
from nine core ACME POCT individuals to a team of over
100 people in the TVC, many of whom had never worked
together. Once these human resources were identified, it was
imperative to create a culture of teamwork, collaboration, and
streamlined communication with this newly formed, expanded
multi-institutional, and interdisciplinary team. A purposeful
communications strategy was also established to ensure effective
cross-communication among all areas. This included reliance
on Zoom for regular video-conference meetings internally and
externally with companies and the NIH and use of the Microsoft
Teams collaboration and project management platform to facil-
itate strong and effective local project management practices. A
key factor during this initial launch was the engagement of two
Chief Operating Officers (Co-COOs) who provided consistency
and served as central points of communication through attending
all sub core, NIH, and project team meetings to ensure the
aims and goals of RADx Tech were articulated clearly. The Co-
COOs ensured all personnel had consistent instructions and clear
communication on direction and goals to generate the data
and input necessary to quickly yet thoroughly evaluate each
candidate device. Additionally, the Co-COOs participated in
the weekly RADx Tech project report-out meetings, providing
real-time project-specific updates to RADx Tech leadership
teams and NIH leadership, as well as sharing timely feedback
to the TVC on the status of individual projects. Importantly, the
Co-COOs were existing employees at Emory with strong ties
at the partner institutions and hence, had a familiarity with the
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people and systems thus allowing them to effectively and rapidly
promote a team culture and facilitate effective communications.
The TVC began by having weekly meetings with each of the
sub cores (virology, laboratory validation, engineering, clinical
site and specimen related) that were focused on setting up the in-
frastructure, gaining consensus on testing protocols, establishing
a useful workflow and communication strategy, and determining
which sites and labs would be involved in each project. As
time went on and each sub core was established more fully,
many of these meetings evolved into twice weekly “all cores”
meetings, focused on TVC-wide operational discussions and
study sections whereby discussions would focus on recently
tested technologies and the data generated from such, additional
NIH requests for timely input from experts at the TVC, and
other topics relevant to multiple TVC sub cores. Routinely 40+
individuals participated in the TVC all cores meetings, with
multiple representatives from each sub core (see Fig. 1(b)) in at-
tendance. The various disciplines represented provided a wealth
of knowledge and expertise to refine and expand the TVC’s
approach to testing the novel diagnostics on behalf of the NIH.
Importantly, leadership representatives from the institutional
Offices of Research Administration were also heavily involved
and invested in the successful TVC launch and were devoted to
providing ongoing careful oversight. At the start, weekly meet-
ings with the Emory Vice President for Research Administration,
departmental leaders, and leaders from key operational offices
including sponsored programs, technology transfer, research
administration, environmental health and safety, and the Institu-
tional Review Board (IRB) were convened with TVC leaders and
the Co-COOs to enable quick attention and effective remedies
to address barriers and challenges as they arose. These meetings
laid the foundation for streamlining of processes and evaluations
– such as template agreements that could be used with RADx
Tech companies – and served as a forum to determine how best
to address the complexities and challenges with some of the
companies. Dedicated attention, collaboration and support from
administrative leadership at all the partner institutions (Emory,
GT, Children’s) helped tremendously with multiple challenges
such as identifying available and qualified research personnel,
expediting Material Transfer and Data Use Agreements, IRB
amendments, and troubleshooting subcontracting issues just to
name a few.
III. ENGINEERING DESIGN AND HUMAN FACTORS SUB CORE
The original ACME POCT Technology Development & Re-
finement core was already staffed with a multi-disciplinary team
of skilled engineering staff and faculty based at GT and Emory.
The existing technical expertise of the team (chemistry, physics;
and mechanical, electrical, and biomedical engineering) allowed
for consideration of the challenges presented by novel SARS-
CoV-2 tests and included individuals with experience in fluid
mechanics and microfluidics, point-of-care diagnostics, medi-
cal devices, micro-electromechanical systems, optical sensors,
device usability and human factor design. Usability, design, and
human factors expertise was added to the engineering sub core
team to effectively pivot and comprehensively meet the TVC
needs.
The engineering core performed three essential functions
within the TVC. First, when a technology was introduced into
the core workflow, initial evaluation of the maturity of the
technology within the context of technology readiness levels
was established using a benchmarking method for assessing
the maturity of acquired technologies [13]. Using this evalu-
ation framework, the maturity of incoming technologies was
rated on a 9-point scale ranging from technologies in the idea
phase, through prototyping, validation, and production [14].
Many technologies that came through the engineering core were
pre-production systems that had been or were currently being
validated in the intended operating environment. This maturity
assessment provided insight to TVC and RADx Tech leadership
into how much work from a technical perspective would be
required for each technology to reach commercialization, pro-
viding a roadmap of the steps necessary to reach a state suitable
for consumer use.
Second, after assessing the maturity of a technology, the
engineering core provided a thorough analysis of device design
and function. Sometimes preceded by technical discussions with
company staff and NIH project leadership, this analysis typi-
cally involved device disassembly and a detailed assessment of
individual components within the technology. This assessment
allowed the Engineering Design and Human Factors sub core
to provide feedback on potential failure modes and engineering
best practices, in turn allowing the overall team to understand
reasons for technology failures, to 1) help the companies iter-
atively improve their technologies, and 2) assist the laboratory
and clinical-based sub core teams with test operation. Among
the challenges of this assessment were the diversity of sample
types (swabs, saliva, breath) and sampling methods, finding
suitable lab space for device disassembly and analysis in this
new remote-work environment, test target molecules (RNA or
protein antigen), and signal transduction mechanisms (electronic
or optical, and visual or non –visual). Furthermore, given sig-
nificant concern of SARS-CoV-2 exposure to lab personnel
involved in testing and patients when interacting with these
devices, the Engineering Design & Human Factors sub core
performed a biosafety analysis to identify potential sources of
device contamination and suggested mitigation practices. This
critical role of this sub core allowed for proactive adoption of
careful use and practice to avoid biosafety issues and protect test
validation personnel as well as our patient volunteers.
Finally, the Engineering Design & Human Factors sub core
analyzed materials and manufacturing choices that went into
device design using both information provided by the company
and physical analysis of the technology. The engineering core
communicated these findings directly to the RADx Tech large-
scale commercialization core that had been established by the
NIH to facilitate the manufacturing scale up of successful tech-
nologies (see article by Walsh et al. in this special issue). This
analysis provided this group a “head start” so they were prepared
for the challenges that needed to be overcome for manufacturing
and scalability of these technologies, and could begin to address
these challenges prior to receiving the technology [15].
Device usability testing aligned with human factors was
performed by HomeLab, a multi-disciplinary team of faculty
and staff based at GT who focus on user experience research,
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human factors, industrial design, and mechanical and electrical
engineering [16]. HomeLab allowed for a thorough evaluation
of device usability considerations for multiple user groups, the
assessment of viability of potential use cases, and the develop-
ment of objective recommendations for device improvement to
be relayed to project teams.
Technologies were evaluated to determine the viability for the
intended (and potential) use cases using a variety of methods,
depending on factors such as timeline, target end user, and
device development stage. Evaluation methods included expert
reviews, in-depth expert evaluations, design failure modes and
effects analyses, heuristic analyses, use case simulations, user
observations, and user testing. Challenges to device evaluation
included short timelines, limited numbers of devices to assess,
and communication of technical assessments to the larger center.
Each usability evaluation had to be tailored to the technology
and individual circumstances. For a device that was early in the
design cycle, focus was placed on providing actionable feedback
that could be rapidly incorporated into the design changes. For
a device that was further along in the design process, emphasis
was placed on details of the product design or recommendations
for the instructions for use that would result in reduced risk or
enhanced user satisfaction.
The engineering research team also provided recommenda-
tions to improve the design of the protocol, device, and/or
instruction materials through a comprehensive usability report
that included results of human factors analyses, results of sim-
ulations and accessibility measurements, user feedback, and a
comprehensive rating scale that contributed to informed TVC
reviews. Some common examples of recommendations include
increased font size and reorganization of the instruction materi-
als to increase accessibility and comprehension for the user, as
well as physical adjustments to the devices to allow users with
reduced dexterity to better use the device. The engineering team
also used common convention and design principles to make
recommendations on what would be most intuitive to users to
decrease frustration and reduce the risk of errors. The device
development stage was factored into recommendations, with
emphasis placed on recommendations that would be feasible
to implement in a short time period.
The TVC at CAPCaT also supported the advancements of
several different technologies that went through the standard
RADx Tech review process by standard validation and usability
testing. CAPCaT contributed through development of new lab
experimental setups to mimic physiological relevant conditions
in a laboratory setting, such as with a nasal tissue model to
test and refine new swab designs in the pre-clinical stage of an
injection molded swab.
IV. CLINICAL TRANSLATIONAL VALIDATION
The original ACME POCT Clinical and Translational Vali-
dation Core experienced the most expansion and specialization
upon the launch of the TVC. The preexisting ACME POCT
clinical leaders were instrumental in identifying, attracting and
recruiting the additional expertise necessary for the specialized
evaluation of the COVID-19 detection process. The expansion
was deemed necessary in three key areas as described below.
A. Virology Sub Core
Immediately upon the TVC launch, a critical need was iden-
tified for testing live virus under controlled laboratory condi-
tions to enable thorough device testing. While interrogating
human samples from COVID-19 infected patients would un-
doubtedly play a central role in the evaluation process, use
of live virus allowed for the generation of data under care-
fully controlled conditions to report accurate sensitivity and
specificity results reflecting utility of these technologies de-
signed to detect SARS-CoV-2 antigens and/or viral nucleic
acids. Existing access to a biosafety level-3 (BSL-3) labora-
tory and already trained personnel with decades of experience
with BSL-3 standard operating procedures were instrumental
in enabling the ACME POCT TVC to provide this indispens-
able device verification platform. This was accomplished via
collaboration and combined contributions from two existing
Emory-based laboratories, one in the Laboratory of Biochemical
Pharmacology and the other within the Division of Pediatric
Infectious Disease. These labs were staffed by a combination
of faculty and staff who shared protocols and resources, split
tasks based upon staff availability. Personnel were responsible
for preparing virus stocks, troubleshooting tests, writing reports,
meeting with project teams and their NIH liaisons and discussing
new projects and identifying critical new collaborations. While
the two labs provided some level of redundancy to allow for
testing of multiple devices at one time, they also provided a
level of specialization due to their access to and use of different
virus strains. Specifically, one lab used USA-WA1/2020 and
Australian strain CoV/Victoria/1/2020 and the other lab used
USA-CA3/2020, Italy-INMI1, and USA-GA4/2020. The latter
strain is a virus isolate sourced from a locally hospitalized patient
that was used to expand the rigor and significance of our device
testing protocols. All isolates were propagated at low passage
levels in our laboratories and titration was performed using
the TCID50 method. Additional specialized expertise at Emory
was used to perform viral sequencing and PCR quantification
of the produced stocks. Overall, these collective arrangements
allowed for a very functional, efficient, and customizable way
to thoroughly evaluate devices using live virus, and moreover
highlights our ability to capitalize on area strengths to provide
comprehensive and rigorous testing approaches.
The Virology sub core experts also served as functional part-
ners to the private companies and academic inventors and/or NIH
Team Leads, through their preparation of LOD testing protocols,
LOD testing, and reporting of the operational performance of
the evaluated tests (LOD and practicality). The LOD of the
tests was objectively determined by using serial dilutions of live
SARS-CoV-2 of known concentrations in relevant pooled neg-
ative human samples including saliva and nasal swab matrixes.
This sub core was responsible for obtaining and propagating
emergent SARS-CoV-2 isolates/variants to expand the testing
capabilities as previously described.
The creation of this sub core initially faced several challenges
including (i) a need to rapidly recruiting additional qualified
personnel and training them for BSL-3 work, (ii) PPE and disin-
fectant shortage (iii) the need for rapid implementation of new
Biosafety SOPs and obtaining their approval by the Environmen-
tal Health and Safety Office (EHSO) in the context of evolving
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safety guidelines and regulations (iv) limited access to reagents
such as the viral isolates and (v) new equipment requirements.
These challenges were addressed in a timely manner in large
part due to the aforementioned institutional leadership focus and
partnership. For example, despite an Emory-wide hiring freeze,
this sub core was granted specialized exceptions to quickly post
job openings, recruit, and hire to meet critical personnel needs.
B. Clinical Population Testing & Sample Collection
Sub Core
This sub core included adult and pediatric arms, and each
group had two main aims. The first aim was to conduct in-
vivo testing to determine the performance characteristics of test
platforms by testing directly in the patient population, and the
second was to amass a collection of a variety of human samples
including nasopharyngeal swabs, nasal swabs, oropharyngeal
swabs, and saliva samples to bank for future ex-vivo testing.
These aims were largely accomplished via four sites including
1) a Children’s sponsored pediatric drive-thru testing site; 2)
an Emory-based adult stand-up site created specifically for this
purpose; 3) a Grady Memorial Hospital-based site dedicated
to healthcare staff and inpatient testing; and 4) both hospital-
based and Emergency Department recruitment from Children’s,
Emory (both Emory University Hospital and Emory University
Hospital Midtown) and Grady Memorial Hospital. These sites
were staffed by clinical research coordinators and clinical re-
search nurses with oversight by faculty researchers who were
responsible for training, consenting, data collection and direct
device testing [8].
Upon TVC launch, this sub core had to quickly identify
suitable sites that produced the necessary variety in patient pop-
ulations to meet potential testing needs. This included asymp-
tomatic and symptomatic adults and children in different areas
of metro Atlanta while maintaining proximity to the applicable
biorepository. The Children’s drive-thru was an existing site
operationalized on May 11, 2020, to meet the testing needs of
the pediatric population but had been scheduled to dissolve July
1, 2020. The sub core capitalized on the opportunity to keep that
facility operational for the duration of TVC. This extension of
operations provided a win-win outcome and is a good example
of successfully capitalizing on a synergy between clinical and
research operations. The Children’s drive-through was the first
established clinical site for the TVC and recruited over 3000
children between June 2020 and January 2021. Establishment of
the adult research sites required additional negotiations between
research and clinical healthcare teams to incorporate the research
protocols alongside the established clinical operations. Success
grew from a close partnership including the engagement of the
onsite clinical managers at each adult site to ensure a smooth
working relationship and establishing an atmosphere to allow
both sides to articulate their individual and collective needs
to operate harmoniously while still meeting individual goals.
Ultimately, recruitment was accomplished from all established
sites with little disruption to the clinical testing workflows, which
was the most common obstacle.
The creation of the TVC biorepository was also an early
activity. The Department of Pediatrics had a preexisting re-
search biorepository which rapidly adapted existing processes
for sample receipt, processing and storage, inventory manage-
ment and sample distribution to internal and external labs. Some
customization was necessary including coordinating courier ser-
vices to new and multiple locations, protocol development for
new sample type processing and storage, customizing and link-
ing laboratory inventory management systems with the clinical
database, and diversion of effort and training new personnel to
meet the scope and scale of the project. The relatively small and
already established pediatric biorepository operation was able to
nimbly and successfully pivot and expand to accommodate the
TVC needs. The pediatrics personnel then provided consultation
and input to adapt their processes and share their experiences
with their adult counterparts so that they too could establish a
parallel adult-focused sample biorepository. The CAPCaT TVC
also provided access to SARS-CoV-2 clinical samples through a
large, existing biorepository at UMMS, which has an established
relationship with the Department of Pathology in the affiliated
University of Massachusetts Medical Center, Worcester, MA. In
May 2020, the UMMS biorepository adapted its procedures to
collect, process and store remnant clinical human samples from
the clinical system, including nasopharyngeal swabs, saliva,
serum, and plasma. The swabs and saliva samples were assayed
by RT-PCR using the TaqPath COVID-19 Combo Kit (Applied
Biosystems).
This sub core also played an essential role in verifying and
collecting clinical data for RADx Tech-supported companies’
Emergency Use Authorization (EUA) applications. The organi-
zation and breadth of our testing sites have allowed for collection
of both fresh and banked samples and the ability to query these
databases to meet the unique study needs. This sub core has
generated important sensitivity and specificity data, as well
as practical usability data (produced in collaboration with the
aforementioned HomeLab) that has been incorporated in the
final TVC recommendation of each device. Feedback from the
clinical research nurses and coordinators on instruction for use
documents and overall design of some devices during verifica-
tion have led to improvements and ultimately better products to
begin the EUA process.
Several barriers were encountered related to successful re-
cruitment and sample collection that had to be addressed to
ensure success within the TVC. The mix of adult and pediatric
samples had to be carefully coordinated since the two laboratory
information management systems (LIMS) were not linked, due
to pediatric and adult operations using different vendors for their
electronic medical record systems and consistent records were
needed to comply with FDA part 11 research record keeping
compliance. Another challenge experienced was when compa-
nies requested biorepository samples be shipped to them so that
they could do their own testing rather than send their device to the
TVC. Especially early on, there were very few banked samples
available for testing off site so TVC Leadership was tasked with
making decisions when a company’s request for scarce ex vivo
samples could be accommodated without compromising on-site
TVC operations and testing.
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Given the variety and capacity of the clinical sites, this team
was able to pivot quickly to coordinate and test multiple devices
at a time when the number of devices entering the TVC workflow
increased. The clinical team worked with the Co-COOs to match
the devices to the best sites and to coordinate the time the
testing for each one based on current volume and positivity rates.
Communication was key to avoid straining the team while also
capitalizing on the full system capacity. Unique devices that
required specialized sample types not yet encountered, such as
taking measurements from exhaled breath, presented challenges
that were addressed through our diverse team-based approach.
The unique requirements presented in these situations required
collaboration among all the sub cores to determine safety and
usability with a major focus on ensuring there would be no trans-
mission of virus between patients and testers. In this example,
to ensure a thorough assessment, input from clinical experts in
the pulmonology field was sought utilizing their established best
practices with forced expiratory volume tests and the associated
cleaning practices to ensure our usability test protocols were
conducted with the highest safety standards across all sub cores
and clinical population testing sites.
C. Clinical Laboratory Assessment Sub Core
The Clinical Laboratory Assessment sub core had three aims.
The first was to perform reference SARS-CoV-2 testing on
samples collected from the research participants recruited at the
clinical population testing sites described above. This reference
result was not only used as a comparator for device testing,
but also as a comparator for patient specimens saved in the
biorepository. The second was to “test the test.” This consisted of
evaluating the numerous devices submitted to the TVC to help
inform the recommendation regarding the clinical utility and
value of the device. The third purpose was to consult with in-
dustry and the inventors upon request to discuss their devices and
advise the manufacturers on usability parameters to improve.
Four existing laboratory sites were leveraged for this
work – 1) the Advanced Diagnostics Laboratory in the Chil-
dren’s clinical lab; 2) the Emory/Children’s Laboratory for
Innovative Assay Development (ELIAD); 3) the Emory Investi-
gational Clinical Microbiology Core; and 4) the Grady Memorial
Hospital Clinical Microbiology Laboratory. At the launch of
the TVC, these sites were already staffed by licensed medical
technologists, research technicians, and post-doctoral fellows
although the volume of work from RADx Tech necessitated
recruitment of additional staff to assure rapid turn-around time.
Within these laboratories, there were several platforms for
routine clinical SARS-CoV-2 testing by RT-PCR using assays
that had received EUA and that can be used as comparators.
The Children’s site acquired a Panther Fusion (Hologic, Marl-
borough, MA) instrument and a Liaison (Diasorin, Cypress,
CA) for their SARS-CoV-2 reference testing. The ELIAD site
referred molecular testing to Emory Medical Laboratories or
the other sites. The Investigational Clinical Microbiology Core
developed a multiplex SARS-VoV-2 real-time RT PCT assay
that was validated against FDA authorized diagnostics [17].
This research-use assay provided a flexible method for use
with a variety of specimen types and perhaps even more im-
portantly, could be modified to detect emerging variants. The
Grady Clinical Microbiology Laboratory used the Alinity M
(Abbott Molecular, Des Plaines, IL). While there was initial
discussion about standardizing reference testing across sites, the
group ultimately decided to follow protocols at their individual
sites, allowing a breadth of assessment parameters and a “divide
and conquer” capability when multiple devices arrived at the
same time for evaluation.
Each site performed a sequential series of analyses to evaluate
the performance of tests submitted to the ACME POCT TVC.
In many cases, these evaluations included the use of contrived
and coded panels to determine analytic sensitivity (LOD) and
specificity (using the OC43 and MERS coronaviruses), before
testing with authentic clinical samples. The workflow at all
Clinical Laboratory Assessment sub core sites was multi-fold.
Before a device was scheduled for delivery to the TVC, key
representative members of this sub core met with the company
or assay development team by Zoom to discuss the principles of
the assay, existing data on assay performance, and other specifics
which might affect the performance testing. This information
was used to select the form of inactivated SARS-CoV-2 used in
testing (assays designed to detect viral antigen were typically
evaluated using gamma-irradiated virus, while heat-inactivated
virus was used when evaluating RNA detection assays), the
matrix (saline, UTM, VTM, saliva, and serum), and the specific
dilution range to focus on testing. The next steps consisted of
a team effort of creating the testing panels, sample coding, per-
formance testing, recording results, and then finally unblinding
the samples to collate the results.
While this was the typical pattern for testing, at times cus-
tomization of testing protocols was necessary. For example,
some devices were too large or the technology was not suffi-
ciently mature to ship to the TVC. In these cases, this sub core
prepared and coded assay panels as described above, and then
shipped the panels to the companies for testing. Additionally,
the TVC was occasionally asked to evaluate an assay where
the devices could be shipped, but a company representative
visited on site to assist with some of the challenges of operating
the instruments. In these cases, a standard approach was used,
making sure all the individuals involved in testing were blinded
to sample identifiers.
While some assays performed considerably below accept-
able specifications, many others yielded promising results. This
raised the question of how to compare the performance of the
better assays, since they were often very different technologies.
One approach to addressing this problem was to collect SARS-
CoV-2-positive nasopharyngeal swabs from the participating
biorepositories, pool the samples, and then freeze the resulting
pool in single-use aliquots. This approach eliminated several
problems: the results were not affected by inactivation methods,
the matrix was one of the most commonly used for diagnostics,
the exact same sample could be used for several different de-
vices, the testing could be performed in the BSL-2 enhanced
laboratory, and the aliquots were sufficiently concentrated that
several 10-log dilutions could be performed to objectively com-
pare sensitivity of assays to each other.
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At the end of the testing phase, detailed performance reports
were prepared by each laboratory site and the data were collated
along with the data generated by the Virology sub core. A
comprehensive data assessment was facilitated by the Clinical
Laboratory Assessment evaluation team to determine if the test
performance justified further testing using authentic clinical
samples. That testing was initiated if the initial performance
LOD was sufficiently good.
There were multiple barriers in scaling up a clinical laboratory
to meet the new demands of the TVC, especially during an
already resource-constrained pandemic. Barriers included re-
duced availability of instruments to purchase, which necessitated
forging a close relationship with the vendor who supplied instru-
ments as soon as they were available. There were also signifi-
cant issues with availability of supplies including shortages of
PPE, pipette tips, gloves, transport media, and collection swabs.
Thanks to the national RADx Tech infrastructure, the large-
scale commercialization core was able to help acquire scarce
supplies. Access to qualified laboratory personnel was also an
initial constraint. Although at the TVC launch there were well
qualified staff in place, the volume of the TVC work required
the addition of skilled laboratory personnel to accommodate
the pace and workload. The central Emory Human Resources
office was enlisted to in part to help address this by providing
lists of personnel from labs whose research had ramped down
at the beginning of the pandemic. In fact, this same principle
was used to quickly meet many of the workforce needs across
the TVC. In this particular case, since the clinical volumes for
routine clinical testing decreased during the pandemic because
of decreased patient volume, it was possible to utilize technical
and management personnel placed on part-time furlough. This
allowed for technical support that knew the details of test valida-
tion, and who also knew how to “get things done” in a hospital
system to become part of the TVC team. The doctoral staff, while
fully engaged with daily duties, were flexible with their work to
accommodate the multiple meetings and testing of the devices.
Overall, a commitment from Children’s and Emory research,
purchasing, finance, and administrative teams was instrumental
in supporting the TVC initiative.
V. REGULATORY SUB CORE
The need for regulatory expertise to assist technology de-
velopers to navigate the Emergency Use Authorization process
became increasingly vital as the COVID-19 pandemic unfolded
and it was clear that an accelerated timeline of FDA approval
was needed. Furthermore, as the RADx Tech portfolio of can-
didate devices grew and diversified and guidance from FDA
was developed and evolved, project teams were in great need of
continued regulatory consultation. Early in the TVC initiative, it
was clear that project teams would need to compile and organize
regulatory resources as rapidly as possible. As such, the ACME
POCT greatly expanded its pre-existing regulatory team and
assigned a dedicated operations lead and facilitator. Together,
the team connected with regulatory experts in other RADx Tech
centers to create a unified effort to address the needs of the
growing number of projects.
The regulatory sub core consisted of four team members from
GT, Emory, and an outside consulting firm with experience in
regulatory operations and coordination. Team members were
assigned to specified RADx Tech projects to provide customized
support per unique project and its technology needs. Examples
of customized support included regulatory strategies, frequent
project consultations, drafting and/or review of: Pre-EUA and
EUA submissions, clinical protocols, product labeling, Instruc-
tions for Use (IFU), Quick Reference Guide (QRG), and Fact
Sheets.
An instrumental element of support can be attributed to a suc-
cessful working relationship with the FDA. Agency leadership
within the Office of In Vitro Diagnostics and Radiological Health
worked closely with the Regulatory sub core. Key highlights of
this collaboration include 1) Prioritization of RADx Tech Pre-
EUA and EUA submissions 2) Weekly status review of RADx
Tech submitted Pre-EUA and EUA submissions, 3) Weekly
general question and answer meetings 4) Weekly individual
project meetings to discuss those assays intended for Point of
Care or at-home use and 5) planning for clinical evaluation of
new technologies via method comparison studies. Key func-
tions carried out by this sub core included: 1) The creation
of regulatory strategies and tools, compilation and submission
of EUA with project teams, 2) Organization and facilitation of
meetings designating Clinical Laboratory Improvement Amend-
ments (CLIA), Point of Care (POC) & Laboratory Developed
Test (LDT), 3) Communication with FDA on pre-EUA and
EUA status, 4) collaboration with FDA to determine appropri-
ate clinical evaluation designs and 5) Collaboration with other
TVC sub cores to ensure sufficient data to support regulatory
packages.
This dedicated sub core team aided in the development of U.S.
Regulatory strategies for the teams developing SARS-CoV-2 de-
tection devices. A challenge in this work was the varying levels
of experience working with FDA on the part of the private com-
panies and academic inventors. However, this sub core was able
to work closely with FDA to recommend standards/consensus
standards and guidance documents to support least burdensome
regulatory approaches and assisted in the creation of and review
of Risk Analyses (in conformance with appropriate guidance/
industry and FDA standards, for example ISO 14971) [18],
[19]. Specifically, the FDA worked with this sub core to create
clinical evaluation protocols by confirming use case (ranging
from high and moderate complexity lab use, waived/point-of-
care use, and home use), the type(s) of samples to be tested
(spanning all upper and lower respiratory specimens and saliva),
how many samples, the appropriate comparator assay, number
of operators, sites and appropriate acceptance criteria. This
led to the execution of successful clinical studies that were
used to support EUA, which has enabled several RADx Tech
teams to realize their goals and market their finished products
in the field.
VI. TVC LESSONS LEARNED
Reflections and recommendations that have emerged from
the TVC include the following (see Table I): 1) Interdisciplinary
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TABLE I
REFLECTIONS AND RECOMMENDATIONS FROM THE RADX TECH TEST
VERIFICATION CORE
collaboration among academic researchers, inventors, funders
and policy makers, and representatives from clinical users of
devices throughout the development, research and decision-
making process allows for quick decisions and course correc-
tions, and improves the use of government funds for device
development; 2) Discussion of timelines and project deliver-
ables among device developers, researchers and policy-makers
enables each group to be more responsive to each other and
allows each group to be more aligned; 3) Communicating project
plans and data derived from device testing from interdisciplinary
contexts is often challenging. Understanding and translating
findings in a way that is sufficient to make “go / no go” decisions
from one context to another in a quickly moving and audience
of multiple stakeholders is critical; 4) A rapidly developing and
changing epidemic in which devices are at varying technology
readiness levels greatly affects study designs and must be ac-
counted for when planning and evaluating testing devices; 5)
Elegant and/or novel device design is not necessarily an indicator
of performance, usability, or scalability. Sometimes the most
effective test for a new target is the repurposing of existing
platforms with proven technology approaches; 6) Academic
researchers can improve their work from the inclusion of others
that they may see as their competitors (e.g., those who compete
for similar funding resources) and those from other disciplinary
areas (e.g., engineers, clinical staff, and regulatory specialists)
to learn different perspectives and approaches; 7) It is important
to continue building US device testing capacity as a means of
training future generations of scientists and device developers
in order to create an established process and field of accelerated
device development in preparation for future public health emer-
gencies (see also article by DiMeo et al. in this special issue).
One of the true assets of the TVC has been the tremen-
dous teamwork and built-in redundancies within some of the
infrastructure. With the ebb and flow of when devices were
delivered for testing, there were many occasions where multiple
assays were being evaluated at the same time. This involved uti-
lization of both BSL-3 laboratories, more than one BSL-2, mul-
tiple clinical sites, usability evaluations and the biorepositories.
Additionally, the TVC and its involvement of both an adult and
pediatric health system ensured that tests were being evaluated
with both pediatric and adult patients. Additionally, key to the
success of the TVC was the deliberate and strategic partnership
that was developed between the project team and federal contacts
at NIH and the FDA which facilitated our inter-institutional
collaboration, communication, and relationship-building.
VII. CONCLUSION
While device test results from this initiative will be published
in future papers, the process and experience of launching the
TVC has been an instructive experience that warrants sharing
to generalize the knowledge gained. There is agreement among
the TVC faculty and staff who have worked in RADx Tech that
it has been one of the most rewarding projects of our careers.
For many of us, we considered this project an honor and our
contribution to the worldwide effort to combat the COVID-19
pandemic. Over 100 faculty and staff across our respective
institutions participated and the TVC team has been involved in
the assessment of >50 different devices, more than 20 of which
are now in phase 2 of clinical testing, regulatory approval, and
scale up with others already released to the market more likely
to follow [20].
The end goal of the RADx Tech was to develop and evaluate
novel COVID-19 testing devices and thus contribute to the
national effort to improve large scale diagnostic testing efforts.
While doing this, the TVC harnessed the best practice of collabo-
ration and communication to quickly develop our team as well as
the evidence base for each device. Future efforts will be made to
build a sustained collaborative platform for device development
using the RADx Tech model beyond the COVID-19 pandemic
to facilitate continued accelerated device development for other
clinical needs and sharing of lessons learned.
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